Quantum Genomics and Biolab Sanus Pharmaceutical have signed an exclusive agreement for firibastat in Latin America Quantum Genomics has granted an exclusive license to Biolab Sanus Pharmaceutical to develop and commercialize firibastat for the treatment of hypertension in Latin America. READ THE PRESS RELEASE Quantum Genomics enters into exclusive negotiations for its first partnership The Company has entered into exclusive negotiations with a leading cardiology laboratory in South America to sign its first regional partnership. READ THE PRESS RELEASE Quantum Genomics Launches Study of Firibastat in Patients with Renal Failure The enrollment of the first patient in the study is expected in September 2019 and the results of the study are expected in April 2020. READ THE PRESS RELEASE Quantum Genomics Announces Positive FDA Feedback on Phase III Program Design of Firibastat in Resistant Arterial Hypertension Quantum Genomics announced receiving a favourable feedback from the U.S. Food and Drug Administration (FDA) regarding the Company’s Phase III development plan and trial design for firibastat in patients with resistant arterial hypertension. READ THE PRESS RELEASE Quantum Genomics Selected to Enter the European Rising Tech Label Quantum Genomics Quantum has been selected to enter the European Rising Tech label, recognizing the most promising Tech SMEs listed on Euronext markets. READ THE PRESS RELEASE
Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially high blood pressure and heart failure.